Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 394 | 0.85 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 13385
Sealed predictions
- MAFF in dopamine neurons, braak-0.01 (p 0.982) → -0.32 (p 0.407)receipt 13393
Swarm cases
receipt 13393: MAFF in dopamine neurons, braak
- power
- full sample -0.29 (p 0.239, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.176, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.118, n 18). could be the mix.
- skeptic
- leave-one-out range -0.45 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.239, n 18). fragile.
- cell type
- strongest in microglia: -0.67 (p 0.0023, n 18) vs -0.29 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAFF in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MAFF · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.18 p 0.534 (needs p < 1.7e-4)
Receipts
loading the receipts